Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$27.77 - $64.4 $52 Million - $121 Million
-1,873,311 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$54.9 - $105.21 $27,065 - $51,868
493 Added 0.03%
1,873,311 $118 Million
Q3 2021

Nov 15, 2021

SELL
$105.0 - $178.37 $16.3 Million - $27.6 Million
-154,997 Reduced 7.64%
1,872,818 $197 Million
Q2 2021

Aug 16, 2021

BUY
$125.11 - $180.0 $5.71 Million - $8.22 Million
45,649 Added 2.3%
2,027,815 $359 Million
Q1 2021

May 13, 2021

SELL
$126.27 - $191.71 $1.1 Million - $1.67 Million
-8,694 Reduced 0.44%
1,982,166 $264 Million
Q4 2020

Feb 12, 2021

SELL
$81.94 - $135.34 $58,587 - $96,768
-715 Reduced 0.04%
1,990,860 $269 Million
Q3 2020

Nov 12, 2020

BUY
$73.3 - $89.48 $189,553 - $231,395
2,586 Added 0.13%
1,991,575 $166 Million
Q1 2020

May 13, 2020

BUY
$39.1 - $62.9 $14 Million - $22.5 Million
358,389 Added 21.98%
1,988,989 $102 Million
Q4 2019

Feb 14, 2020

BUY
$29.79 - $43.06 $4.22 Million - $6.1 Million
141,600 Added 9.51%
1,630,600 $67.8 Million
Q3 2019

Nov 14, 2019

BUY
$30.47 - $37.65 $3.14 Million - $3.87 Million
102,900 Added 7.42%
1,489,000 $48.2 Million
Q2 2019

Aug 14, 2019

BUY
$25.73 - $35.79 $23.7 Million - $33 Million
922,345 Added 198.89%
1,386,100 $48.3 Million
Q1 2019

May 10, 2019

BUY
$21.71 - $31.54 $1.06 Million - $1.54 Million
48,755 Added 11.75%
463,755 $13.7 Million
Q4 2018

Feb 13, 2019

BUY
$14.95 - $24.72 $2.47 Million - $4.08 Million
165,000 Added 66.0%
415,000 $9.64 Million
Q3 2018

Nov 13, 2018

BUY
$17.8 - $25.35 $4.45 Million - $6.34 Million
250,000 New
250,000 $4.87 Million

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.95B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.